Table of Contents
ISRN Oncology
Volume 2011 (2011), Article ID 219064, 6 pages
Review Article

Lymph Node Staging with Choline PET/CT in Patients with Prostate Cancer: A Review

1SCDU Medicina Nucleare 2, ASO S. Giovanni Battista, Corso Bramante, 88, 10126 Torino, Italy
2Centro PET, IRMET SpA, Via Onorato Vigliani, 89/A, 10138 Torino, Italy

Received 14 October 2011; Accepted 13 November 2011

Academic Editor: A. E. Bilsland

Copyright © 2011 Andrea Skanjeti and Ettore Pelosi. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Due to its prevalence, prostate cancer represents a serious health problem. The treatment, when required, may be local in case of limited disease, locoregional if lymph nodes are involved, and systemic when distant metastases are present. In order to choose the best treatment regimen, an accurate disease staging is mandatory. However, the accuracy of conventional imaging modalities in detecting lymph node and bone metastases is low. In the last decade, molecular imaging, particularly, choline PET-CT has been evaluated in this setting. Choline PET represents the more accurate exam to stage high-risk prostate cancer, and it is useful in staging patients with biochemical relapse, in particular when PSA kinetics is high and/or PSA levels are more than 2 pg/ml. The present paper reports results of available papers on these issues, with particular attention to lymph node staging.